CARBAMAZEPINE

USDailyMed:Carbamazepine AU:D N03AF01(WHO) AU:S4(Prescription only)BR:Class C1(Other controlled substances)CA:℞-onlyUK:POM(Prescription only)US:℞-only 5H-dibenzo[b,f]azepine-5-carboxamide 298-46-4Y85756-57-6 2554 5339 DB00564Y 2457Y 33CM23913M D00252Y CHEBI:3387Y ChEMBL108Y DTXSID4022731 Interactive image c1ccc2c(c1)C=Cc3ccccc3N2C(=O)N InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)YKey:FFGPTBGBLSHEPO-UHFFFAOYSA-NY Carbamazepine, sold under the brand nameTegretolamong others, is ananticonvulsant medicationused in the treatment ofepilepsyandneuropathic pain.It is used as an adjunctive treatment inschizophreniaalong with other medications and as asecond-lineagent inbipolar disorder.Carbamazepine appears to work as well asphenytoinandvalproatefor focal and generalized seizures.It is not effective forabsenceormyoclonic seizures. Carbamazepine was discovered in 1953 by Swiss chemist Walter Schindler.It was first marketed in 1962.It is available as ageneric medication.It is on theWorld Health Organization's List of Essential Medicines.In 2023, it was the 185th most commonly prescribed medication in the United States, with more than 2million prescriptions. Photoswitchableanalogues of carbamazepine have been developed to control its pharmacological activity locally and on demand using light (photopharmacology), with the purpose of reducing the adverse systemic effects of the drug.One of these light-regulated compounds (carbadiazocine, based on a bridgedazobenzeneordiazocine) has been shown to produce analgesia with noninvasive illuminationin vivoin a rat model ofneuropathic pain.